Skip to main content
. 2018 Jun 21;24(23):2457–2467. doi: 10.3748/wjg.v24.i23.2457

Figure 1.

Figure 1

Vedolizumab targets the α4β7 integrin, preventing leucocyte translocation from the blood into the inflamed gut tissue. MadCAM-1: Mucosal addressin cell adhesion molecule.

HHS Vulnerability Disclosure